STOCK TITAN

Harrow Q3 2026 revenue reaches record $99M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Harrow, Inc. (HROW) furnished its November 2026 investor presentation for the Jefferies Global Healthcare Conference. Q3 2026 revenue was $99 million, described as a record, up 39% from Q3 2025 and 41% from Q2. Branded revenue was $83 million, adjusted EBITDA was $21 million, and branded gross margin was 79.3%. VEVYE, IHEEZO and TRIESENCE together generated $75 million; their revenue grew 75%, 15% and 186%, respectively, year over year.

Harrow lists full-year 2026 revenue guidance of $350 million to $365 million and Q4 adjusted EBITDA of $33 million or more. It says the TYRVAYA acquisition closed October 1, with first revenue expected in Q4 2026 and more than $30 million in expected 2027 revenue. G-MELT’s NDA submission is expected by year-end 2026, with a potential early-2028 launch. The IHEEZO QUELL Phase 4 study did not meet its primary non-inferiority endpoint.

2 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

How the balance works

Positive

  • Moderate pointQ3 revenue reached $99 million, up 39% year over year.
  • Moderate pointCore-brand revenue growth: VEVYE 75%, IHEEZO 15%, TRIESENCE 186%.

Negative

  • Major pointThe 231-patient QUELL Phase 4 study missed its primary non-inferiority endpoint.

Filing Explained

The presentation’s capital-structure snapshot lists $75 million in cash and $300 million of unsecured notes carrying 8.625% and due in 2030, giving readers the disclosed cash balance and the notes’ amount, interest rate and maturity.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Q3 2026 revenue $99 million Described as a record; up 39% from Q3 2025
Year-over-year revenue growth 39% Q3 2026 compared with Q3 2025
Branded revenue $83 million Q3 2026
Adjusted EBITDA $21 million Q3 2026; non-GAAP measure
Branded gross margin 79.3% Q3 2026
Full-year revenue guidance $350 million–$365 million 2026
Q4 adjusted EBITDA outlook $33 million or more Q4 2026
Expected TYRVAYA revenue More than $30 million Expected 2027 revenue
adjusted EBITDA financial
"Q3 $21 Adjusted EBITDA"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
permanent J-code regulatory
"Paid under its own product-specific permanent J-code."
Permanent J-code is a standardized billing code in the HCPCS Level II system assigned by the Centers for Medicare & Medicaid Services to identify a specific injectable drug or biologic for use in claims and reimbursement. It replaces temporary or miscellaneous codes and creates a consistent label—like giving a medicine a permanent SKU—that insurers and providers use to bill and track use. For investors, a permanent J-code can make revenue forecasts, market uptake and reimbursement comparisons clearer because it improves coding stability and pricing transparency.
non-inferiority medical
"Primary endpoint of non-inferiority not met."
A non-inferiority trial is a type of clinical test designed to show a new treatment is not meaningfully worse than an existing standard by more than a pre-set, acceptable amount. Think of it like proving a new smartphone model has battery life close enough to the leading model while offering other advantages; for investors, a successful non-inferiority result can clear the way to regulatory approval and market uptake even when the new option isn’t superior in headline effectiveness.
NDA regulatory
"NDA Submission Expected by year-end 2026"
An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.
Orange Book patents regulatory
"Orange Book patents run to 2039"
anti-VEGF biosimilar medical
"OPUVIZ Anti-VEGF biosimilar Launch 2027"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is HROW’s 2026 revenue guidance?

Harrow lists full-year 2026 revenue guidance of $350 million to $365 million. At the low end of that annual guidance, the presentation gives implied Q4 revenue of $135 million and adjusted EBITDA of $33 million or more.

Did HROW’s IHEEZO QUELL study meet its primary endpoint?

No. The Phase 4 study’s primary non-inferiority endpoint was not met. The presentation reports cumulative pain through 24 hours of 2.9 versus 3.7, ocular surface staining mean increases of +1.7 versus +3.2, adverse events of 27% versus 47% with none serious, and pain at injection of 2/5 in both arms.

How much revenue does HROW expect from TYRVAYA in 2027?

Harrow expects more than $30 million in 2027 revenue from TYRVAYA, which the presentation identifies as a dry eye nasal spray. It says the acquisition closed October 1, was funded with cash, and first revenue is expected in Q4 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
FALSE000136021400013602142026-11-162026-11-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 16, 2026
HARROW, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3581445-0567010
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
1A Burton Hills Blvd., Suite 200
Nashville, Tennessee
37215
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (615) 733-4730
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par value per shareHROWThe Nasdaq Stock Market LLC
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934: Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨



Item 7.01. Regulation FD Disclosure.
The Company is furnishing as Exhibit 99.1 to this Current Report on Form 8-K a corporate presentation that may be used by management in connection with investor conferences and meetings with investors.
The information in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits.
99.1
Harrow Corporate Presentation dated November 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HARROW, INC.
Dated: November 16, 2026By:/s/ Andrew R. Boll
Name:Andrew R. Boll
Title:President & Chief Financial Officer

Investor Presentation Jefferies Global Healthcare Conference London | November 2026


 

Jefferies Global Healthcare Conference | London | November 2026 Safe Harbor 2 This presentation contains “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Harrow, Inc. (the “Company” or “Harrow”). Some of these risks and uncertainties include, but are not limited to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration related to compliance and quality plans at our outsourcing facility in New Jersey; and physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission, including its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements are qualified in their entirety by this cautionary statement. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Harrow expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. The Company’s compounded formulations are not FDA approved. All trademarks, service marks and trade names included in this presentation are the property of their respective owners. This presentation refers to non-GAAP financial measures, specifically adjusted EBITDA. A reconciliation and/or further description of any non-GAAP measures with the most directly comparable GAAP measures are included in the Company’s Letters to Stockholders, available on its website. All content included in this presentation is intended for investors and the investment community and is not intended as marketing material or for use by healthcare professionals and their patients. D I S C L O S U R E S


 

Jefferies Global Healthcare Conference | London | November 2026 H A R R O W A T A G L A N C E Harrow. We Are Ophthalmic Pharma. 3 Founded to deliver safe, effective, accessible, and affordable eye medications. The Broadest U.S. Portfolio In Eye Care More prescription eye products than anyone else in the U.S. Three Core Brands Are Driving Growth VEVYE, IHEEZO, and TRIESENCE … all in early growth stages. A Commercial Platform Built To Carry More Four sales teams; Structured to handle planned growth of new product launches in growing categories each year into 2030.


 

Jefferies Global Healthcare Conference | London | November 2026 F I N A N C I A L S Financial Snapshot and 2026 Outlook Five years of growth. A record third quarter. 4 $72.5M $88.6M $130.2M $199.6M $272.3M $357.5M 2021 2022 2023 2024 2025 2026 Guidance Annual Revenue ($M) 2026 Is The Guidance Midpoint Q3 2026 $99.3M Revenue 41% growth vs. Q2 $83.5M Branded Revenue $21.2M Adjusted EBITDA 79.3% Branded Gross Margin 2026 Guidance $350M–$365M Full Year 2026 Revenue $33M+ Q4 Adj. EBITDA 41% Revenue CAGR, 2020–2025 62% Adj. EBITDA CAGR, 2020–2025 Five-Year Track Record $75.3M Cash $300M Unsecured Notes 8.625%, due 2030


 

Jefferies Global Healthcare Conference | London | November 2026 T H R E E D R I V E R S O F V A L U E Driver One: Growth 5 1 Growth Three brands. All early in their run. VEVYE | IHEEZO | TRIESENCE 2 Operating Leverage The platform is built. Revenue now grows faster than cost. Four Sales Teams | One Cost Base 3 Growth Acceleration Planned growth of new product launches in growing categories each year into 2030. TYRVAYA | OPUVIZ | G-MELT | YOCHIL +


 

Jefferies Global Healthcare Conference | London | November 2026 D R I V E R O N E : G R O W T H Three Brands Drive The Growth Q3 2026 vs. Q3 2025 6 D R Y E Y E D I S E A S E $39.7M 75% G R O W T H Revenue vs. last year Total prescriptions up 83% O C UL A R A N E S TH E S I A $25.3M 15% G R O W T H Revenue vs. last year Unit demand up 21% I N JE CT A BL E S T E RO I D $10.7M 186% G R O W T H Revenue vs. last year Unit demand up 110% $75.7M Combined. 76% of total revenue or 91% of total branded revenue 1 2 3


 

Jefferies Global Healthcare Conference | London | November 2026 D R I V E R O N E : G R O W T H | V E V Y E VEVYE: A Big Market, Barely Treated 93% of diagnosed U.S. dry eye patients are not on a prescription. 7 38M+ Americans with dry eye symptoms 16.4M Diagnosed U.S. adults 9.0M Moderate-to-severe disease 1.2M On prescription therapy Growing 20% a year for the past 2 years Water-free The only water-free cyclosporine for dry eye disease ~22x More cyclosporine into the cornea vs. Restasis Day 15 Significant improvement, sustained to 56 weeks 99.8% Of patients report no or mild pain on use 2039 Orange Book patents run to 2039 1 2 3


 

Jefferies Global Healthcare Conference | London | November 2026 D R I V E R O N E : G R O W T H | V E V Y E VEVYE: Record Quarter, Revenue Up 75% vs. Q3 2025 Total prescriptions, net price, and insurance coverage are all rising. 8 $16.0M $21.5M $18.6M $22.6M $25.9M $20.9M $29.4M $39.7M Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26 Q3 '26 VEVYE Quarterly Revenue ($M) +83% Total Rx growth from Q3 2026 vs. Q3 2025 +35% Sequential quarterly revenue growth ~3x Sales team expansion (2026) 10M+ Newly covered commercial lives begin January 1, 2027 Net price is rising Revenue +35% vs. TRxs +17% (Q3 vs. Q2), as more Rxs are insurance covered 1 2 3


 

Jefferies Global Healthcare Conference | London | November 2026 D R I V E R O N E : G R O W T H | I H E E Z O IHEEZO: Under 2% of a 14M-Procedure Market A patented gel ocular anesthetic for in-office eye procedures. Paid under its own product-specific permanent J-code. 9 38,931 48,755 51,545 62,814 45,354 65,477 62,210 Q1 Q2 Q3 Q4 IHEEZO Customer Unit Demand 2025 2026 +21% Unit demand vs. Q3 2025 ~14M+ Annual U.S. in-office procedures Q4 ~25% Historically strongest quarter Net price increase effective July 1, 2026 QUELL IVI study secondary endpoints: • Less pain through 24 hours • Less ocular surface damage • Fewer adverse events • Same pain at injection in both arms 1 2 3


 

Jefferies Global Healthcare Conference | London | November 2026 D R I V E R O N E : G R O W T H | T R I E S E N C E TRIESENCE: Unit Demand Up 110% vs. Q3 2025 FDA-approved preservative-free injectable steroid for the eye 10 4,367 5,547 9,551 10,2659,934 14,603 20,022 Q1 Q2 Q3 Q4 TRIESENCE Customer Unit Demand 2025 2026 $10.7M Record revenue; First $10M+ quarter 7M+ Potential U.S. uses a year in eye inflammation 96% Covered lives; ~$38 average out-of-pocket TRIESENCE catalysts: • Cataract surgery inflammation data (1H 2027) • Next-Gen TRIESENCE (H-N08) NDA (2027) • Next-Gen launch (H2 2028–H1 2029) 1 2 3


 

Jefferies Global Healthcare Conference | London | November 2026 T H R E E D R I V E R S O F V A L U E Driver Two: Operating Leverage 11 1 Growth Three brands. All early in their run. VEVYE | IHEEZO | TRIESENCE 2 Operating Leverage The platform is built. Revenue now grows faster than cost. Four Sales Teams | One Cost Base 3 Growth Acceleration Planned growth of new product launches in growing categories each year into 2030. TYRVAYA | OPUVIZ | G-MELT | YOCHIL +


 

Jefferies Global Healthcare Conference | London | November 2026 D R I V E R T W O : O P E R A T I N G L E V E R A G E 2026: The Commercial Platform Is Built and Paid For Same cost base from Q2 to Q3 drove 41% more revenue … our hiring is paying off. 12 SG&A as a Share Of Revenue 84% First Half 2026 54% Q3 2026 • Q3 revenue rose 41% from Q2. • The expanded team is fully deployed. • New products will be sold by these four teams. 1 2 3 Ocular Surface Disease 3X growth in 2026; ~40 seasoned TYRVAYA reps Retina BYOOVIZ launched in July 2026; OPUVIZ launch in 2027 Access+ Compounded medicines Surgical 3X growth in 2026


 

Jefferies Global Healthcare Conference | London | November 2026 D R I V E R T W O : O P E R A T I N G L E V E R A G E Flat SG&A; 78% Incremental Adjusted EBITDA Conversion Q3 revenue up $28.6M vs. Q2 on flat SG&A ($53.3M in Q2, $53.1M in Q3). 2026 by quarter, Q1 to Q3 actuals. 13 $44.2M $70.7M $99.3M $43.2M $53.3M $53.1M Q1 Q2 Q3 Revenue vs. SG&A ($M) Revenue SG&A ($12.7M) ($1.2M) $21.2M Q1 Q2 Q3 Adjusted EBITDA ($M) 78% Adjusted EBITDA increased ~$22.4M on $28.6M of incremental revenue, Q2 to Q3 Implied Q4 at the low end of 2026 guidance: $135.8M revenue and $33M+ Adjusted EBITDA 1 2 3


 

Jefferies Global Healthcare Conference | London | November 2026 T H R E E D R I V E R S O F V A L U E Driver Three: Growth Acceleration 14 1 Growth Three brands. All early in their run. VEVYE | IHEEZO | TRIESENCE 2 Operating Leverage The platform is built. Revenue now grows faster than cost. Four Sales Teams | One Cost Base 3 Growth Acceleration New products fit within the existing commercial infrastructure. Planned growth of new product launches in growing categories each year into 2030. TYRVAYA | OPUVIZ | G-MELT | YOCHIL +


 

Jefferies Global Healthcare Conference | London | November 2026 D R I V E R T H R E E : G R O W T H A C C E L E R A T I O N A New Product Every Year Into 2030 Each team grows its lead brand today, and adds new product launches in growing categories sold to the same customers. 15 1 2 3 2026 LAUNCHED / ACQUIRED 2027 LAUNCH READY 2028 P IPELINE 2029 P IPELINESALES TEAM Ocular Surface Lead: VEVYE Retina Lead: IHEEZO Surgical Lead: TRIESENCE TYRVAYA Dry eye nasal spray Acquired October CR-01 Ocular cancer device Potential Launch 2029/2030 BYOOVIZ Anti-VEGF biosimilar Launched July 1 OPUVIZ Anti-VEGF biosimilar Launch 2027 YOCHIL Anxiolytic Expected Launch 2028 BYQLOVI Post-op inflammation Launch Q4 G-MELT Sedation tablet Expected Launch 2028 Next-Gen TRIESENCE Prefilled steroid Launch H2 2028–H1 2029


 

Jefferies Global Healthcare Conference | London | November 2026 D R I V E R T H R E E : G R O W T H A C C E L E R A T I O N New Revenue Is Already Arriving Two products already selling in 2026. A bigger one comes in 2027. 16 D R Y E Y E N A S A L S P RA Y >$30M Expected 2027 revenue • The only nasal spray for dry eye. • Closed October 1. • Funded with cash. • First revenue in Q4 2026. • Together with VEVYE, positions Harrow to build a leading dry eye disease franchise, supported by one expanded commercial team. L UC E N TI S - R E FE R E N C E D B IO S I M I L AR July 1 2026 launch • Ordering accounts grew every month of Q3. • More accounts than planned. • Smaller first orders. • Demand built in September and into Q4. E Y L E A - R E FE R E N C E D B IO S I M I L AR 2027 Planned launch • A larger opportunity than BYOOVIZ. • Same retina accounts, same team. • BYOOVIZ lessons shape the launch. 1 2 3


 

Jefferies Global Healthcare Conference | London | November 2026 D R I V E R T H R E E : G R O W T H A C C E L E R A T I O N | G - M E L T G-MELT: Sedation Without The IV A tablet under the tongue. No needle. No opioid. 17 • 3 mg midazolam plus 50 mg ketamine in one tablet. • Dissolves in ~3 seconds under the tongue. • If approved, the only on-label sedation product for cataract surgery. • NDA filing moved up to 2026 from the first half of 2027. 5M+ U.S. Cataract Surgeries / Year The first target market 100M+ Short Procedures Potential in several large markets Commercial plan: replace our compounded MKO Melt, used by 800+ U.S. institutions, turning a cash-pay product into one we expect to be reimbursed. Next: YOCHIL. A pediatric midazolam/anxiolytic ODT tablet. Potential launch in 2028. 7M+ pediatric procedures a year, with adult label expansion planned. Path To G-Melt Launch Pre-NDA Meeting With FDA Completed Q4 2026 NDA Submission Expected by year-end 2026 Potential FDA Approval Q4 2027 Potential Launch Early 2028 1 2 3


 

Jefferies Global Healthcare Conference | London | November 2026 D R I V E R T H R E E : G R O W T H A C C E L E R A T I O N Catalysts Through 2027 What to watch between now and the end of next year. 18 Q4 2026 G-MELT NDA Submission Ahead of the first-half 2027 plan By year-end 2026 TYRVAYA First Revenue First quarter after the October 1 close Q4 2026 January 2027 VEVYE Coverage Win National plan with 10M+ commercial lives Effective January 1 QUELL Full Results IHEEZO Phase 4 study, 231 patients Hawaiian Eye & Retina Early 2027 Full-Year 2026 Results With 2027 annual revenue guidance Early 2027 TRIESENCE Study Data First data, ocular inflammation Early 2027 2027 Investor Day (NYC) First CR-01 findings. March 2027 OPUVIZ Launch EYLEA biosimilar 2027 G-MELT FDA Action Date Assumes standard review Expected Q4 2027 1 2 3


 

Jefferies Global Healthcare Conference | London | November 2026 S U M M A R Y Investment Summary: Why Harrow Three drivers of value, each already showing up in the numbers. 19 1 Growth Three core brands (VEVYE, IHEEZO and TRIESENCE), all early in their growth. $99.3M Record Q3 2026 revenue, up 39%; 84% branded $75.7M Three core brands in Q3; 91% of branded revenue +75% | +15% | +186% VEVYE, IHEEZO and TRIESENCE revenue vs. Q3 2025 2 Operating Leverage The commercial platform is built. Revenue now grows faster than cost. 84% → 54% SG&A as a share of revenue, first half 2026 to Q3 +$28.6M Q3 revenue vs. Q2, with SG&A flat ($53.3M to $53.1M) 78% Incremental adjusted EBITDA conversion, Q2 to Q3 3 Growth Acceleration At least one new product a year, in growing categories, into 2030 – sold by existing teams. 3 Products added in 2026: BYOOVIZ, TYRVAYA, BYQLOVI 2027 OPUVIZ launch; G-MELT NDA by year-end 2026 1+ New product a year into 2030 Today I see a disconnect between our stock’s performance and the operational progress we have made… what is in our control is consistent operational execution, which I believe is a remedy to the disconnect. MARK L. BAUM · Chief Executive Officer · 29th Letter to Stockholders (Q3 2026)“


 

Thank You Growth. Operating leverage. Growth acceleration. Jefferies Global Healthcare Conference London | November 2026 Mike Biega VP, Investor Relations & Communications mbiega@harrowinc.com


 

Jefferies Global Healthcare Conference | London | November 2026 A P P E N D I X | E X H I B I T The Full Portfolio 21 Commercial Products Product Use Sales Team VEVYE Dry eye disease Ocular Surface TYRVAYA Dry eye disease (nasal spray) Ocular Surface FRESHKOTE PF Lubricant eye drops (OTC) Ocular Surface FLAREX Corticosteroid Ocular Surface VERKAZIA Vernal keratoconjunctivitis Ocular Surface ZERVIATE Antihistamine Ocular Surface NATACYN Antifungal Ocular Surface IHEEZO Ocular anesthesia Retina BYOOVIZ Anti-VEGF biosimilar Retina IOPIDINE Eye pressure control Retina TRIESENCE Injectable corticosteroid Surgical, Retina VIGAMOX Antibiotic Surgical, Retina MAXIDEX Corticosteroid Surgical NEVANAC NSAID Surgical ILEVRO NSAID Surgical TOBRADEX ST Antibiotic + steroid Surgical MAXITROL Antibiotic + steroid Surgical ImprimisRx Compounded medications Access+ Launches And Pipeline Product Use Status BYQLOVI Post-op inflammation and pain Launch Q4 2026 OPUVIZ Anti-VEGF biosimilar (EYLEA) Launch 2027 G-MELT Sedation for cataract surgery NDA by year-end 2026. Launch 2028. YOCHIL Pediatric sedation NDA H2 2027 / H1 2028. Launch 2028. Next-Gen TRIESENCE (H-N08) Prefilled injectable steroid Expected H2 2028 to H1 2029 CR-01 Ocular cancer delivery device Phase 2 proof of concept. Potential 2029/2030. Ocular Surface Retina Surgical Access+ Commercial products by sales team, plus anticipated launches and development-stage programs


 

Jefferies Global Healthcare Conference | London | November 2026 A P P E N D I X | S O U R C E S Sources 22 Slide 4. Q3 2026 press release, including the condensed balance sheet. Annual revenue: Harrow Corporate Presentation, November 2026, slide 7. Implied Q4 Adjusted EBITDA of more than $33M: 29th Letter to Stockholders. Slide 6. Product revenue table, Harrow 29th Letter to Stockholders (Form 8-K, Exhibit 99.2, November 9, 2026). Year-over-year growth and the 76% and 91% shares are calculated from that table. Prescription and unit demand: Q3 2026 press release. Slide 7. Farrand et al., Am J Ophthalmol 2017;182:90-98 (16.4M diagnosed adults). Prevent Blindness (2019). IQVIA. FDA Orange Book. Preclinical ex-vivo corneal penetration data on file. Harrow Corporate Presentation, November 2026, slide 12. Slide 8. Quarterly VEVYE revenue: Harrow Corporate Presentation, November 2026, slide 13. Prescriptions, sales team, coverage win: Q3 2026 press release and 29th Letter to Stockholders. Slide 9. Unit demand, market size and J-code: Harrow Corporate Presentation, November 2026, slides 19 to 21. QUELL topline results (Phase 4, n=231, IHEEZO vs. routine anesthesia; Q3 2026 press release): cumulative pain through 24 hours 2.9 vs. 3.7; ocular surface staining mean increase +1.7 vs. +3.2; adverse events 27% vs. 47%, none serious; pain at injection 2/5 in both arms. Primary endpoint of non-inferiority not met. Slide 10. Harrow Corporate Presentation, November 2026, slides 25 and 26. Study timing: Q3 2026 press release. Slide 12. Team expansion: Harrow Corporate Presentation, November 2026, slide 4. Four teams, HarrowRx, TYRVAYA personnel: Q3 2026 press release. SG&A share is calculated: nine-month SG&A of $149.7M less Q3 SG&A of $53.1M, over first-half revenue of $114.9M; Q3 SG&A of $53.1M over Q3 revenue of $99.3M. Slide 13. Q1 revenue ($44.2M), SG&A ($43.2M) and Adjusted EBITDA ($(12.7)M): Q1 2026 press release, May 11, 2026. Q2 is calculated from nine-month results in the Q3 2026 press release: revenue of $214.2M less Q1 and Q3 = $70.7M; SG&A of $149.7M less Q1 and Q3 = $53.3M; Adjusted EBITDA of $7.3M less Q1 and Q3 = $(1.2)M. Incremental conversion = Adjusted EBITDA +$22.4M ÷ revenue +$28.6M, Q2 to Q3 (78%). Implied Q4 = low end of 2026 guidance less reported nine-month results: $350.0M − $214.2M = $135.8M revenue; Adjusted EBITDA of more than $33M per the 29th Letter to Stockholders. Slides 15, 23–24. Harrow Corporate Presentation, November 2026, slides 5 and 9. Q3 2026 press release. Slide 16. Harrow Corporate Presentation, November 2026, slides 14 and 18. BYOOVIZ launch commentary: 29th Letter to Stockholders. Slide 17. Harrow Corporate Presentation, November 2026, slides 27 and 28. NDA timing: Q3 2026 press release. Slide 18. Harrow Corporate Presentation, November 2026, slide 29. Slide 19. Multiples: Trefis (HROW Nov 11, GKOS Oct 22), GuruFocus (OCUL Nov 9), PitchBook (TARS Nov 6), 2026. P/S = market cap ÷ trailing revenue. 5-year range: FY2021–25 year-end and current (companiesmarketcap.com, Stock Analysis; OCUL from market cap/revenue). EV: Stock Analysis; Business Quant (TARS). Revenue CAGR 2020–2025 from reported revenue; Tarsus CAGR is 2023–2025, since the XDEMVY launch, and not directly comparable. Growth-adjusted P/S = P/S ÷ revenue CAGR; n/m for Tarsus. CEO quote: 29th Letter to Stockholders. Slide 20. Harrow Q3 2026 press release (Form 8-K, Exhibit 99.1, November 9, 2026): revenue, branded revenue, guidance. Five-year growth rate (2020 to 2025) and launch cadence: Harrow Corporate Presentation, November 2026, slides 4, 5 and 7. Slide 22. Harrow Corporate Presentation, November 2026, slides 5, 9, 11, 18 and 24. Non-GAAP Measures. Adjusted EBITDA is net income (loss) excluding stock-based compensation, interest, taxes, depreciation, amortization, loss on extinguishment of debt, litigation settlement gains and other non-recurring items. Reconciliations are in Harrow’s Letters to Stockholders. Product Comparisons. Comparisons are for illustration only. No head-to-head clinical trials have been run. Statements reflect FDA-approved labeling and public information. Trademarks. All third-party trademarks belong to their owners and are used for identification only.


 

Filing Exhibits & Attachments

4 documents

Keep reading